Archives
-
How Inhibitors Accelerate p38α Dephosphorylation
2026-09-07
The reference study shows that some kinase inhibitors do more than block p38α catalytic activity: they reshape the activation loop so WIP1 can remove its activating phosphate more efficiently. This dual-action mechanism provides a structural framework for designing inhibitors that suppress signaling both immediately and through accelerated pathway shutoff.
-
Protecting Mechanistic Truth in Cancer Protein Studies
2026-09-07
A translational framework for connecting protease control with mechanistic cancer biology, using the ciclopirox–bioenergetics–ER stress axis as a case study and positioning an EDTA-free cocktail for more reliable protein workflows.
-
Protease Inhibitor Cocktail in Alzheimer’s Assays
2026-09-05
Discover how a Protease Inhibitor Cocktail can preserve TALDO1-centered metabolic evidence in Alzheimer’s disease research. This guide connects EDTA-free inhibitor chemistry with Western blotting, co-immunoprecipitation, kinase assays, and proteomics-aware experimental design.
-
HyperFluor™ 594 in Atherosclerosis Assays
2026-09-04
Discover how a goat anti-rabbit IgG secondary antibody can translate atherosclerosis gene evidence into spatially resolved fluorescence data. This article connects ISG20 validation, spectral assay design, and application-specific controls for more defensible immunological measurements.
-
Sulfaphenazole Optimization for Safer Anti-TB Leads
2026-09-04
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP 2C9 inhibition, a liability associated with potential drug–drug interactions. Compound 10d emerged as the clearest lead, combining a reported MIC of 5.69 μg/mL with CYP 2C9 inhibition above 10 μM and low cytotoxicity.
-
AmpliFold Capture-and-Release for LFA Sensitivity
2026-09-03
The ChemRxiv study introduces AmpliFold, a capture-and-release architecture that temporarily sequesters HER2-containing complexes before triggered release and high-affinity rebinding. By expanding the effective capture area and optimizing cleavable Fab conjugates, the approach improved lateral flow assay sensitivity while addressing kinetic limitations associated with low receptor densities and large nanoparticles.
-
BV6 IAP Antagonist: Cell-Death Workflow
2026-09-03
BV6 provides a practical way to probe IAP-dependent survival, apoptosis induction, and radiosensitization in cancer models. This workflow connects concentration-response testing with lysosomal membrane and cathepsin assays, helping researchers distinguish pathway activation from terminal cell damage.
-
Romidepsin (FK228) Workflow for HDAC Research
2026-09-02
Romidepsin (FK228) enables controlled studies of class I HDAC inhibition, chromatin remodeling, cell cycle arrest, and apoptosis. This practical guide connects dose–response experiments with proteomic target-mapping strategies inspired by recent NSCLC research, while emphasizing formulation, timing, and interpretation controls.
-
DMH1 as a Selective ALK2 Inhibitor
2026-09-02
DMH1 provides a focused way to perturb BMP–ALK2 signaling in intestinal organoids and non-small cell lung cancer models. This guide connects pathway readouts with practical dosing, formulation, migration, and differentiation workflows while separating established product findings from assay recommendations.
-
Clozapine Workflows for Schizophrenia Research
2026-09-01
Build reproducible Clozapine experiments around receptor pharmacology, ERK1/2 signaling activation, and liver-safety readouts. This workflow also shows how to use the compound as a pharmacological comparator when studying targeted magnetic stimulation and GABRE-related schizophrenia phenotypes.
-
M344: From HDAC Mechanism to Translation
2026-09-01
M344 illustrates how a mechanistically defined histone deacetylase inhibitor can connect chromatin biology with cancer, radiation-response, differentiation, and viral-latency research. This thought-leadership guide interprets its reported potency and cell-model activity while emphasizing the translational decisions that matter next: exposure design, orthogonal readouts, toxicity boundaries, biomarker strategy, and combination logic. It also uses the clinical development of degarelix as a separate case study for understanding how compelling pharmacology must mature into decision-grade evidence.
-
ETS1–SENP2–FUNDC1 Axis in Bronchopulmonary Dysplasia
2026-08-31
The reference study identifies ETS1 as a transcriptional regulator of mitochondrial quality control in hyperoxia-induced bronchopulmonary dysplasia. Its proposed mechanism links SENP2-mediated FUNDC1 deSUMOylation to HSPA8-dependent FUNDC1 degradation, suggesting that selective suppression of excessive mitophagy may help preserve lung development.
-
Deuterium-Labeled Degarelix: Efficient Synthesis
2026-08-31
The reference study reports a practical route to deuterium-labeled degarelix acetate for use as an internal standard in absorption, distribution, metabolism, and excretion studies. Its key innovation is microwave-assisted deuteration of a naphthyl amino-acid precursor with D2O/D3PO4, followed by Fmoc-based peptide assembly to give the labeled antagonist in 13 steps and 14% overall yield.
-
Optimizing hiPSC Platelet Differentiation with Small Molecul
2026-08-30
Yue and colleagues developed an optimized differentiation scheme that combines higher embryoid body input, human platelet lysate, cytokine-replacing small molecules, and enhanced megakaryocyte maturation. The resulting platform shortened production to 19 days, generated 14.9 platelets per iPSC, reduced reported costs by 58.3%, and produced platelets capable of thrombin-triggered fibrin clot formation and contraction.
-
Pexidartinib: A Functional Map of TAM Biology
2026-08-29
Pexidartinib (PLX3397) provides a controlled way to interrogate CSF1R-dependent macrophage biology in cancer research. This article connects CSF1R-mediated signaling inhibition with the SPP1-focused tumor microenvironment framework and offers practical assay-design guidance beyond standard viability testing.